

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-18. (Withdrawn)

19. (Currently amended) A GLP-1 derivative having a GLP-1 activity, an amino acid sequence in which glutamine is substituted at the 26th position and asparagine or aspartic acid is substituted at the 34th position in a GLP-1 peptide comprising a substitution of lysine with glutamine at 26th 34th position in a GLP-1 peptide comprising a having an amino acid sequence of GLP-1 (7-36) or its sequence in which one or a few amino acids are deleted, substituted and/or added in the amino acid sequence, and having a GLP-1 activity GLP-1 (7-36) with a modification of the peptide which does not substantially alter the physiological activity thereof.

20. (Currently amended) The GLP-1 derivative according to claim 19, wherein the GLP-1 peptide comprising the is selected from the group consisting of GLP-1 (7-36) or its sequence in which one or a few amino acids are deleted, substituted and/or added in the amino acid sequence, and having GLP-1 activity is GLP-1 (7-36), GLP-1 (7-37), or a GLP-1 (7-36) with a C-terminal amide of GLP-1 (7-36) or, and GLP-1 (7-37) with a C-terminal amide.

21. (Currently amended) The GLP-1 derivative according to claim 19, wherein further comprising a substitution of alanine with serine or glycine is substituted at the 8th position in the amino acid sequence peptide.

22. (Currently amended) [[A]] The GLP-1 derivative according to claim 19, having an wherein the GLP-1 derivative consists of the amino acid sequence shown in SEQ ID NO: 2 ; 5 , or 6 in the sequence listing.

23. (New) The GLP-1 derivative according to claim 21, wherein the GLP-1 derivative consists of the amino acid sequence shown in SEQ ID NO: 2 or 6 in the sequence listing.